NDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAYCOL (cerivastatin sodium) is an oral statin tablet approved in 1997 for lipid management in patients with elevated cholesterol. It works by inhibiting HMG-CoA reductase to lower LDL cholesterol and reduce cardiovascular risk. The product is now in loss-of-exclusivity (LOE) stage with limited remaining patent protection.
LOE Approaching
Moderate competitive pressure (30/100) suggests a crowded statin market with declining exclusivity driving consolidation of brand support teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BAYCOL offers limited career acceleration in a declining product with minimal linked job openings (0). Positions focus on maximizing remaining revenue and managing generic transition rather than innovation or market expansion. This is typically a consolidation or exit-strategy role for pharma professionals.
Brand ManagerField Sales Representative
Worked on BAYCOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.